Your browser does not support accepted Web standards. This site has been redesigned to meet Section 508 accessibility standards for persons with disabilities and to meet W3C recommendations for forward compatibility. If you are using an older browser (Netscape or IE 4.x and older), the site layout will not display correctly. However, all pertinent information should still be viewable. To better view this site, please download a browser that complies with Web standards. For upgrade information, visit [www.webstandards.org/upgrades]. Comments or questions? Email [accessibility@osrhe.edu].

Skip directly to: Content, Search Box, Main Navigation
 
 
 
 

University of Oklahoma

The University of Oklahoma partners with Weather Decision Technologies Inc. to provide the most accurate high-resolution weather information content with detections, predictions and forecasts for its customers using sophisticated and proven weather technology systems.


SouthWest NanoTechnologies Inc. (SWeNT), established by OU, is a development-stage specialty chemical manufacturer, commercializing Single Wall Carbon Nanotubes for high-volume specialty applications. Earlier this year, ConocoPhillips invested capital and intellectual property rights in SWeNT to construct a pilot plant to manufacture single-wall carbon nanotubes at a cost low enough to accelerate their commercialization in several specialty applications.


Photo of Invoveon researchers.With an initial funding from a group of private investors, OU and The Presbyterian Health Foundation, two OU Health Sciences Center physicians established a company based on their invention —a Digital Disease Management System to monitor diabetic patients for diabetic retinopathy. The Invoveon system was successful, and in 1999, a large, publicly traded Chicago-based company took a 30 percent interest in the company.


OU has partnered with Pure Protein Inc. to produce a product based on a breakthrough life sciences technology. Developed by OU Health Sciences Center scientist Dr. William Hildebrand, the technology utilized a method by which certain protein molecules can be mass-produced for use in screening organ transplant recipients’ blood to ensure that the recipients’ defense mechanisms are compatible with the donors. With Hildebrand’s technology, Pure Protein expects to produce such testing substrates at a fraction of the present cost and capture more than half of this market.


Technology developed at OU for systems that produce soluble-form proteins in the bacterium E. coli. has been licensed to Novagen Inc. of Madison, Wisc., giving Novagen exclusive world rights to the technology. Doctoral, graduate and undergraduate students as well as interns served on Dr. Roger Harrison’s research team to develop this technology.


In 2001 Oklahoma City-based Hyalose LLC partnered with Novozymes A/S to produce Hyaluronic Acid (HA) using technologies developed by doctors at the OU Health Sciences Center. Medical uses of HA include treatment of variations of arthritis and joint disease as well as wide ranging applications in ophthalmology, urology, skin care and wound healing. The total market for HA products is $3.8 billion annually.


Photo of a bridge with the SAVA system.Scrub Oak Technologies Inc. manufactures a patented semi-active vibration absorber (SAVA), an electronically monitored “shock absorber” for bridges invented by the late Bill Patten, an OU engineering professor. The SAVA system compensates for the pounding bridges get from heavy traffic and could extend the lives of thousands of aging highway bridges throughout the country.


OU and NanoBioMagnetics Inc. (NBMI) of Oklahoma City established a Collaborative Research Agreement under which the two organizations are exploring the use of magnetically responsive nanoparticles in a range of human health applications. NBMI is developing proprietary technology in the use of magnetically responsive nanoparticles as Organ-Assisting-Devices in the emerging field of nanomedicine. NBMI is focusing on OADs for drug delivery and organ bioswitches and will work with OU in validating developed technologies in human health applications.